RT Journal Article
SR Electronic
T1 Performance of point of care assays for hepatitis B and C viruses in chronic kidney disease patients
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP jclinpath-2018-205024
DO 10.1136/jclinpath-2018-205024
A1 Jakeline Ribeiro Barbosa
A1 Vanessa Faria Cortes
A1 Moyra Machado Portilho
A1 Juliana Custódio Miguel
A1 Vanessa Alves Marques
A1 Cristianne Sousa Bezerra
A1 Natalia Vasconcelos de Souza
A1 Danielle Malta Lima
A1 Jeová Keny Baima Colares
A1 Lia Laura Lewis-Ximenez
A1 Elisabeth Lampe
A1 Livia Melo Villar
YR 2018
UL http://jcp.bmj.com/content/early/2018/05/05/jclinpath-2018-205024.abstract
AB Aims Point of care testing (POCT) has been used for hepatitis B and C diagnosis in general population, but little is known about the influence of clinical conditions in the accuracy of these assays. This study aims to evaluate the performance of POCTs for detection of hepatitis B virus surface antigen (HBsAg) and antibodies to Hepatitis C Virus (anti-HCV) in Chronic Kidney Disease (CKD) patients.Methods A total of 286 subjects were included in this study. HBsAg and anti-HCV were detected using commercial EIAs and four POCTs: HBsAg (WAMA Imuno-Rápido HBsAg and VIKIA HBsAg) and anti-HCV (DOLES HCV teste rápido and WAMA Imuno-Rápido anti-HCV) in serum and whole blood.Results Using EIA, HBsAg and anti-HCV prevalence was 4.5% and 16.1% in CKD patients. HBsAg and anti-HCV POCTs had sensitivities from 92.3% to 100% and 84.8% to 89.1% while specificities were 99.3% to 100% and 99.2% to 99.6%, respectively. POCT using serum samples performed well compared with whole blood samples and true positive samples of POCTs had high optical density to cut-off (OD/CO) values compared with EIA.Conclusions This study demonstrates good performance of HBsAg and anti-HCV POCTs in CKD patients, especially in serum samples indicating low interference of this disease in the performance of these assays. POCTs could be an important tool for HBV and HCV screening in high-risk populations.